Vertex Pharmaceuticals Incorporated $VRTX Stock: Fisher Asset Management LLC Boosts Position

Fisher Asset Management LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 17.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,676 shares of the pharmaceutical company’s stock after acquiring an additional 4,198 shares during the period. Fisher Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $14,992,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Global Investments bought a new position in Vertex Pharmaceuticals in the second quarter worth $3,568,000. Danica Pension Livsforsikringsaktieselskab purchased a new position in Vertex Pharmaceuticals during the second quarter valued at $13,823,000. UNIVEST FINANCIAL Corp bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $4,495,000. State Street Corp boosted its holdings in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after buying an additional 141,320 shares in the last quarter. Finally, Meeder Advisory Services Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $3,187,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $538.60 on Monday. The business has a 50 day moving average of $522.37 and a 200 day moving average of $483.84. The firm has a market cap of $136.56 billion, a PE ratio of 34.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a twelve month low of $412.27 and a twelve month high of $568.67. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the firm posted $4.80 earnings per share. The company’s revenue was up 11.8% compared to the same quarter last year. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of a number of recent research reports. Daiwa Securities Group upped their target price on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Wells Fargo & Company lifted their price target on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Rothschild & Co Redburn boosted their price objective on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Stifel Nicolaus boosted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the stock a “hold” rating in a research note on Tuesday, November 3rd. Finally, Evercore upped their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $596.44.

Get Our Latest Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Read More

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.